How Winning a Major Australian Wastewater Upgrade With MemCor MBR Technology At DuPont (DD) Has Changed Its Investment Story

E. I. du Pont de Nemours and Company

E. I. du Pont de Nemours and Company

DD

0.00

  • DuPont de Nemours’ MemCor membrane bioreactor system was selected to upgrade Canberra’s Lower Molonglo Water Quality Control Centre, expanding wastewater treatment capacity to about 97 million liters per day and supporting long-term infrastructure resilience for the Australian Capital Territory.
  • This contract reinforces DuPont Water Solutions’ global presence in advanced membrane technologies, which already help purify more than 50 million gallons of water each minute across 112 countries.
  • We’ll now examine how winning a major Australian wastewater upgrade with MemCor MBR technology could influence DuPont’s longer-term investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

DuPont de Nemours Investment Narrative Recap

To own DuPont, you generally need to believe in its shift toward higher value water and healthcare technologies while managing PFAS liabilities and portfolio reshaping. The Canberra MemCor win highlights DuPont’s water capabilities, but it does not materially change the near term focus on executing the Qnity separation and managing ongoing legal and cost pressures that could weigh on margins and cash flows.

Among recent announcements, the August 2026 “beat and raise” quarter, with full year net sales guidance lifted to US$7,160 million to US$7,190 million, ties most directly to this news. Stronger revenue expectations, combined with growing references to water technologies, frame contracts like the Lower Molonglo upgrade as supporting evidence for the water thesis, even as investors continue to watch profitability, legal outflows, and the impact of buybacks and restructuring on per share metrics.

Yet behind DuPont’s water wins, there is still meaningful PFAS and environmental litigation risk that investors should be aware of...

DuPont de Nemours' narrative projects $7.8 billion revenue and $919.6 million earnings by 2029. This requires 4.3% yearly revenue growth and about a $787.6 million earnings increase from $132.0 million today.

Uncover how DuPont de Nemours' forecasts yield a $172.07 fair value, a 24% upside to its current price.

Exploring Other Perspectives

DD 1-Year Stock Price Chart
DD 1-Year Stock Price Chart

Some of the most cautious analysts saw DuPont reaching about US$7.9 billion in revenue and US$888 million in earnings by 2029, which is far more pessimistic than narratives that lean on water growth and portfolio realignment, so it is worth comparing how those darker assumptions might shift after a contract win like Canberra’s MemCor upgrade.

Explore 4 other fair value estimates on DuPont de Nemours - why the stock might be worth as much as 42% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your DuPont de Nemours research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free DuPont de Nemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DuPont de Nemours' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

  • Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
  • We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.